NATCOPHARM - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.9
| Stock Code | NATCOPHARM | Market Cap | 17,142 Cr. | Current Price | 958 ₹ | High / Low | 1,060 ₹ |
| Stock P/E | 11.4 | Book Value | 462 ₹ | Dividend Yield | 0.63 % | ROCE | 31.8 % |
| ROE | 27.5 % | Face Value | 2.00 ₹ | DMA 50 | 919 ₹ | DMA 200 | 912 ₹ |
| Chg in FII Hold | 1.07 % | Chg in DII Hold | -0.48 % | PAT Qtr | 107 Cr. | PAT Prev Qtr | 501 Cr. |
| RSI | 52.9 | MACD | 23.1 | Volume | 6,43,164 | Avg Vol 1Wk | 7,32,485 |
| Low price | 660 ₹ | High price | 1,060 ₹ | PEG Ratio | 0.07 | Debt to equity | 0.03 |
| 52w Index | 74.4 % | Qtr Profit Var | -14.4 % | EPS | 83.8 ₹ | Industry PE | 27.6 |
📊 Analysis: NATCOPHARM is trading at ₹958, above both its 50 DMA (₹919) and 200 DMA (₹912), showing short-term strength. RSI at 52.9 indicates neutral-to-positive momentum, while MACD (23.1) confirms bullish bias. Intraday volume (6.4 lakh) is slightly below the 1-week average (7.3 lakh), suggesting moderate participation. Fundamentals are strong with ROE 27.5%, ROCE 31.8%, and very low debt-to-equity (0.03). Valuation looks attractive with P/E 11.4 vs industry 27.6 and PEG ratio of 0.07, though recent profit decline is a concern.
💰 Optimal Buy Price: Intraday entry may be considered near ₹950–955 if momentum sustains.
🎯 Exit Levels:
- Profit-taking: ₹975 – ₹985 (near-term resistance)
- Stop-loss: ₹940 (below intraday support)
⏱️ If Already Holding: Exit should be considered if price fails to hold above ₹950 or if intraday momentum weakens. Watch for volume spikes near ₹975–985 to book profits intraday.
Positive
- Strong ROCE (31.8%) and ROE (27.5%) indicate efficient capital use.
- Low debt-to-equity (0.03) ensures financial stability.
- EPS of ₹83.8 supports valuation strength.
- FII holding increased (+1.07%), showing foreign investor confidence.
Limitation
- Quarterly PAT declined from ₹501 Cr. to ₹107 Cr. (-14.4%).
- Volume slightly below average, indicating weaker intraday participation.
Company Negative News
- DII holding decreased (-0.48%), showing reduced domestic institutional support.
- Quarterly profit decline raises short-term concerns.
Company Positive News
- Valuation attractive with P/E (11.4) well below industry average (27.6).
- PEG ratio of 0.07 suggests strong growth potential relative to valuation.
- 52-week index return of 74.4% reflects strong investor confidence.
Industry
- Industry PE at 27.6 is much higher, making NATCOPHARM relatively undervalued compared to peers.
- Pharmaceutical sector benefits from defensive demand and export opportunities.
Conclusion
✅ NATCOPHARM shows short-term bullish momentum with price above key moving averages, positive MACD, and neutral RSI. Intraday traders may consider entries near ₹950–955 with profit targets around ₹975–985. A tight stop-loss at ₹940 is recommended. Despite recent profit decline, attractive valuation and strong fundamentals make it a reasonable candidate for intraday opportunities.
Would you like me to extend this into a sector benchmarking overlay comparing NATCOPHARM with peers like Sun Pharma, Dr. Reddy’s, and Cipla to highlight relative intraday strength and rotation opportunities within the pharma sector?